Atrium Therapeutics, Inc. Common Stock (RNA) — Financial Flexibility Index
Atrium Therapeutics, Inc. Common Stock (RNA) has a Financial Flexibility Index of -0.26x as of December 2025. Free cash flow of $-18.37 Million (operating CF $-19.25 Million minus capex $879.00K) represents 0% of total liabilities ($71.07 Million). Check Atrium Therapeutics, Inc. Common Stock strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for Atrium Therapeutics, Inc. Common Stock across 8 annual periods. See working capital position of Atrium Therapeutics, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Atrium Therapeutics, Inc. Common Stock (2018–2025)
Year-by-year free cash flow to debt coverage for Atrium Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Atrium Therapeutics, Inc. Common Stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.56x | $-39.68 Million | $-41.13 Million | $71.07 Million | ▲ +73.6% |
| 2024 | -2.11x | $-293.80 Million | $-300.87 Million | $138.94 Million | ▼ -135.3% |
| 2023 | -0.90x | $-114.84 Million | $-119.06 Million | $127.79 Million | ▲ +59.1% |
| 2022 | -2.20x | $-133.44 Million | $-136.27 Million | $60.73 Million | ▼ -11.4% |
| 2021 | -1.97x | $-91.07 Million | $-94.81 Million | $46.15 Million | ▼ -51.6% |
| 2020 | -1.30x | $-36.02 Million | $-37.12 Million | $27.68 Million | ▼ -7851.3% |
| 2019 | 0.02x | $2.73 Million | $2.49 Million | $162.26 Million | ▲ +107.9% |
| 2018 | -0.21x | $-9.61 Million | $-9.65 Million | $45.11 Million | — |